<DOC>
	<DOCNO>NCT02286167</DOCNO>
	<brief_summary>The primary goal study assess feasibility biologic activity modify Atkins-based diet combine short-term intermittent fasting , GLioma Atkins-based Diet ( GLAD ) , patient central nervous system GBM .</brief_summary>
	<brief_title>Glioma Modified Atkins-based Diet Patients With Glioblastoma</brief_title>
	<detailed_description>Malignant glioma high glycolytic rate dependent glucose energy metabolism . This call `` Warburg effect '' reliance central nervous system ( CNS ) tumor cell glucose utilization glycolysis identify potential therapeutic target cancer metabolism . Preclinically , reduce cerebral glucose via calorie restriction repeatedly associate tumor reduction improve survival glioma animal model . Such work lead several early clinical study evaluate ketogenic diet ( KD ) patient recurrent GBM . The modified Atkins diet ( MAD ) design provide palatable , less restrictive effective alternative strict KD , particularly adult . The MAD require inpatient admission initial fast , weight food , severe dietary restriction generally well tolerate , easy administer , practical adult . The MAD lack calorie restriction , important component dietary therapy preclinical investigation . Emerging evidence also suggest short term fasting may provide superior anti-cancer activity long term calorie restriction benefit observe without substantial weight loss observe long term calorie restriction . In glioma patient , diet therapy combine broad clinical application MAD caloric impact short-term intermittent fast therefore optimal . Moreover , initiation diet cancer already undergone induction therapy clinically radiographically stable , may provide optimal time metabolic intervention prevent recurrence progression .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . Patients must clinical histopathologic diagnosis GBM , complete &gt; 80 % prescribed concurrent radiation therapy adjuvant temozolomide without CTCEA grade 3 4 toxicity , great 7 month time completion concurrent chemoradiotherapy . 2 . Karnofsky performance status &gt; /= 60 . 3 . Patients must least 18 year age . 4 . Patients must eligible undergo ketogenic Atkins base diet accord baseline body mass index ( BMI , see exclusion criterion ) , comorbid medical condition ( see exclusion criterion ) , baseline laboratory assessment ( see exclusion criterion ) . 5 . Patients must appropriate mental capacity sufficient social support able complete require study activity ( i.e . diet record , etc ) able provide write informed consent . 1 . Patients history metabolic disorder include document defect urea metabolism ( include document history gout ) , carnitine deficiency ( primary carnitine deficiency , carnitine palmitoyltransferase I II deficiency , carnitine translocase deficiency ) , fatty acid metabolism , betaoxidation defect , pyruvate carboxylase deficiency , mitochondrial function , porphyria , nephrolithiasis . 2 . Severe acute infection . 3 . BMI &gt; 35.0 BMI &lt; 20.0 . 4 . Active bowel obstruction , ileus , active remote pancreatitis . 5 . Clinically significant heart failure ( NYHA &gt; 2 ) , recent myocardial infarction , symptomatic atrial fibrillation . 6 . Clinically significant renal disease ( creatinine &gt; 2.0 mg/dL , urea &gt; 100 mg/dL ) . 7 . Clinically significant hepatic dysfunction ( alanine aspartate aminotransferase &gt; 7 time upper limit normal ) . 8 . Patients insulindependent diabetes mellitus . 9 . Conditions may increase risk diet significantly reduce compliance ( i.e . cognitive impairment , frank dementia , etc ) . 10 . Other concurrent experimental therapy . 11 . Milk allergy . 12 . Treatment modify Atkins diet ( MAD ) cause within 9 month prior study enrollment 13 . Patient inability complete baseline screen 3day diet record .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>modified-Atkins diet</keyword>
	<keyword>ketogenic diet</keyword>
	<keyword>central nervous system malignancy</keyword>
	<keyword>glioma</keyword>
</DOC>